Slides
Page 1
Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2026 (FY2025) Tokyo Stock Exchange Prime Market | 6523 PHC Holdings Corporation February 12, 2026
Page 2
2 ©PHC Holdings Corporation 2026 Disclaimer This document was prepared by PHC Holdings Corporation (referred to as the “Company,” herein) solely for informational purposes. This document does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in the United States, Japan, or any other jurisdiction. None of the Company’s securities have been or will be registered under the United States Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration oran applicable exemption from registration requirements. This document contains forward-looking statements, that reflect the Company's assumptions, outlook, and estimates based on information available to the Company as well as its plans and expectations, as of the date of this document or other date indicated. Please note that significant differences may arise between the forecasts and other forward-looking statements contained herein and the actual results, due to various factors. Readers are therefore cautioned against placing undue reliance on such forward-looking statements. Additionally, this document includes information that has not been audited or reviewed by an independent certified public accountant or audit corporation. It also contains financial information based on past financial statements or accounting documents, as well as management figures thatare not based on financial statements or accounting documents. Except as required by applicable laws or stock exchange rules and regulations, the Company assumes no obligation to update or revise any information in this document based on any subsequent developments. This document includes information derived from or based on third-party sources, including information about the markets in which the Company operate. Such information is based on statistics and other data from third-party sources as cited herein. The Company has not independently verified and cannot warrant the accuracy or completeness of any information derived from or based on third-party sources. This document is an English translation of the original Japanese language document and has been prepared solely for reference purposes. The Company makes no warranties or assurances regarding the accuracy or completeness of this English translation. In the event of any discrepancy between this English translation and the original Japanese language document, the Japanese document shall prevail in all respects. The information contained in this document is subjectto change without notice. Furthermore, any information about products (including those currently in development) contained in this document is not intended to constitute advertising or medical advice.
Page 3
3 ©PHC Holdings Corporation 2026 Contents Executive Summary FY25Q3 Financial Results Summary FY25 Full Year Forecasts Appendix 01 02 03 04 • Corporate functions have been reviewed. Please refer to page 25 for details. • For the meanings of business-related and financial terms and abbreviations, please refer to page 28.
Page 4
01 Executive Summary
Page 5
5 ©PHC Holdings Corporation 2026 Revenue and operating profit increased YoY, driven by strong performance in the BGM business. However, a cumulative FX loss of JPY 10.5 billion, including primarily unrealized valuation losses, resulted in a YoY decrease in profit attributable to owners of parent. FY25Q3 Financial Highlights (JPY in 100 millions) FY25 Full Year Forecasts FY25 Q3YTD Financial Results Summary 3,631 Revenue 200 Operating Profit 20 Profit Attributable to Owners of Parent 2,693 Revenue 171 Operating Profit 7 Profit Attributable to Owners of Parent +0.9％(+23)YoY Growth +0.5％(+1)YoY Growth -90.9％(-69)YoY Growth +0.4％(+15)YoY Growth -11.4％(-26)YoY Growth -80.9％(-85)YoY Growth While Q3 revenue and operating profit exceeded internal forecasts, the full-year forecast remains unchanged, reflecting a conservative outlook on the business environment. Profit attributable to owners of parent has been revised to incorporate the FX loss of JPY 3.6 billion recorded in Q3. However, the dividend remains unchanged. JPY 42 Dividend Per Share (Interim: JPY 21, Year-end: JPY 21) (JPY in 100 millions) Change from Previous Forecast -Change from Previous Forecast - Change from Previous Forecast -54.5% (-24)
Page 6
6 ©PHC Holdings Corporation 2026 Update on Diabetes Management Business transfer in the U.S. was completed on January 1, 2026. Business in Europe will continue for a period based on TSAs* 1, but there is no profit/loss impact from FY25Q4 onwards. Targeting the -2.4% CAGR (FY25-FY27) outlined in our Value Creation Plan 2027, the U.S. market is performing solidly, with profitability improving through company-wide cost reductions. U.S. Market Environment and Our Status • The U.S. BGM market continues to decline at a high single-digit rate. FY25Q3YTD results: double-digit growth*2, FY25 full-year outlook: high single-digit growth • ASP*3 improved by more than 2% YoY . • Launch of the new product “Contour Plus” has led to more than 50 new commercial contracts which cover more than 80 million lives. • National brand market in OTC*4 channel grew 6%. Maintained #1 position. Cost Improvement Initiatives • FY25 Full-Year Cost Reduction : Approx. JPY 900 million − Partial insourcing of previously outsourced packaging and consolidation of outsourcing partner locations − Shift to low-cost meters − Dual-sourcing for procurement cost and contract renegotiations for logistics cost reduction − Office/warehouse downsizing and streamlining • Additional cost reduction effects equivalent to FY25 are expected for FY26. These initiatives will lead to stable operating profit margins for BGM as follows: FY24 Actual: 24% FY25 Business Plan: 24% / Q3YTD Actual: 29% FY26 and Onward Outlook: 20%~25% *1 Transition Service Agreement *2 Excluding FX impact *3 Average Selling Price *4 Over The Counter BGM CGM （JPY in100 millions） FY24 Actual FY25 Forecast Revenue 30.6 36.0 Operating profit -90.0 -64.0 CGM Performance
Page 7
7 ©PHC Holdings Corporation 2026 Progress of Initiatives in the Value Creation Plan *1 Clinical Laboratory Accreditation Program provided by the College of American Pathologists *2 EcoVadis Sustainability Rating for PHC Holdings Corp: https://recognition.ecovadis.com/D0SVvJqy40azwDNKFzA4jg PHC Group Received Bronze Medal*2 in EcoVadis 2025 Sustainability Assessment PHC Group improved its EcoVadis scores in all categories, Environment, Labor & Human Rights, Ethics, and Sustainable Procurement compared to the previous year, ranking among the top 35% of companies assessed globally. “TwinGuard ECO” Series Expands with Compact Model: -85ºC Non-CFC Dual-Cooling ULT Freezer Expanded the ultra-low temperature freezer lineup with a compact model designed to preserve the quality of biological samples and pharmaceuticals through two independent refrigeration systems while reducing environmental impact via non-CFC refrigerants and lower power consumption. (Japanese) Re-acquisition of ISO15189 Accreditation at the Central Laboratory We will continue to implement corrective actions and recurrence prevention measures to regain trust. URL https://www.phchd.com/global/news/2025/1217 URL https://www.phchd.com/jp/phc/news/2025/1202 URL https://ssl4.eir-parts.net/doc/6523/tdnet/2726311/00.pdf February 1, 2025 Re-certified for the Medical-Related Services Mark June 25, 2025 Obtained updated CAP*1 accreditation November 28, 2025 Re-certified for ISO15189 at the Central Laboratory Cost optimization: “Smart Spend Program” • Set up global procurement organization to lead group-wide cost optimization initiatives • Installed group guidelines that procurement must be involved at early stage to review proposals when expenses are above threshold. • Initiatives developed for major indirect expense items such as facility maintenance, IT, T&E, mobile and PC etc. currently on going. Supply chain and site/organizational optimization • Optimized production at each manufacturing site - Progress toward “lowest cost, closest to customer production,” considering tariff impacts and cost competitiveness • Cost reductions with integration of Japan sales offices and outsourcing cost reduction by utilizing customer service functions • Integration of international warehouses and sales offices Capital efficiency improvement • Sale of non-strategic minority shareholdings and idle assets • Improved working capital by improving terms for payment and receivables and inventory reduction. “Structural Reform to Strengthen the Profit Base” Initiatives for
Page 8
FY25Q3 Financial Results Summary 02
Page 9
9 ©PHC Holdings Corporation 2026 FY25Q3 Results FY24Q3 YTD Results FY25Q3 YTD Results YoY Variance FY24 Q3 Results FY25 Q3 Results YoY Variance Revenue 2,669 2,693 +23 930 959 +28 Operating Profit 170 171 +1 78 67 -11 Profit Before Tax 125 25 -100 51 16 -35 Profit Attributable to Owners of Parent 76 7 -69 35 13 -23 EUR/USD Against JPY 165 / 152 172 / 149 +7 / -4 - - - EBITDA 383 374 -9 147 137 -10 Adjusted EBITDA 383 381 -2 150 139 -11 (JPY in 100 millions)
Page 10
10 ©PHC Holdings Corporation 2026 Quarterly Trends in Revenue and Operating Profit Revenue tends to increase in the latter half of the fiscal year due to seasonality. This quarter again saw solid performance in BGM, coupled with higher demand for the Biomedical business, resulting in increased revenue and profit compared to Q2. On a YoY basis, revenue rose due to favorable FX. However, operating profit declined, due to stagnant market conditions in D&LS and decreased revenue of e-prescription products. Operating ProfitRevenue (JPY in 100 millions) (JPY in 100 millions) 852 887 930 947 839 895 959 FY24 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY25 Q1 FY25 Q2 FY25 Q3 20 72 78 56 38 65 67 FY24 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY25 Q1 FY25 Q2 FY25 Q3 +3.0% +7.1% -13.9%+3.0%
Page 11
11 ©PHC Holdings Corporation 2026 29% 35% 34% 2% Revenue by Segment and Business Unit Revenue Composition (JPY in 100 millions) FY24Q3 YTD FY25Q3 YTD Variance Results Results Excluding FX Impact Results Excluding FX Impact Diabetes Management 742 771 758 +3.9% +2.1% Healthcare Solutions 942 952 952 +1.1% +1.1% LSIM 499 507 507 +1.6% +1.6% Healthcare IT Solutions 379 392 392 +3.4% +3.4% CRO 64 54 54 -16.6% -16.6% Diagnostics & Life Sciences 961 924 924 -3.8% -3.8% Pathology 432 426 426 -1.5% -1.5% Biomedical 382 366 366 -4.2% -4.1% IVD 147 132 132 -9.7% -10.1% Consolidated 2,669 2,693 2,680 +0.9% +0.4% (JPY in 100 millions) Revenue 2,693 Diabetes Management Healthcare Solutions Diagnostics & Life Sciences Others
Page 12
12 ©PHC Holdings Corporation 2026 170 +40 -10 -44 +13 169 +2 171 2,669 +16 +8 +13 -11 -6 -16 -15 +22 2,680 +12 2,693 Analysis of Revenue Growth and Operating Profit Growth Operating Profit* Revenue (JPY in 100 millions) (JPY in 100 millions) FY24Q3 YTD FY25Q3 YTD Excluding FX Impact Diabetes Management Healthcare Solutions Diagnostics & Life Sciences HQ & Others FY25Q3 YTD FX Impact FY24Q3 YTD Diabetes Management LSIM Healthcare IT Solutions CRO Pathology Biomedical IVD HQ & Others FY25Q3 YTD FX ImpactFY25Q3 YTD Excluding FX Impact Revenue Growth Rate +0.4% Operating Profit Growth Rate -0.5% *Corporate functions have been reviewed. Please refer to page 25 for details.
Page 13
13 ©PHC Holdings Corporation 2026 742 771 758 FY24Q3 YTD Total FY25Q3 YTD Total FY25Q3 Excluding FX Impact +3.9% [Diabetes Management Segment] Revenue and Operating Profit Despite the market decline, revenue grew YoY due to the robust performance of BGM in Europe and the U.S., contributions from CGM, and favorable FX impact against the euro. Operating profit grew significantly, driven by higher BGM revenue, enhanced margins with pricing initiatives in the U.S., cost reduction initiatives, and lower amortization expenses. A one-time expense of JPY 400 million related to the CGM transfer was recorded. Operating ProfitRevenue － Market shifts to low-price channel － Market contraction in developed countries + Share gains in developed markets + Increased sales of CGM FY24Q3 YTD Total FY25Q3 YTD Total FY25Q3 Excluding FX Impact 158 189 186 • Margin: 19.1% *Please refer to page 25 for details. Favorable FX impact relative to the euro + (JPY in 100 millions) (JPY in 100 millions) ［Reference］Adjusted EBITDA － JPY 210M impact from corporate function transfer* + Revenue growth in BGM Strong performance in profitable developed countries + Improved profitability in the U.S. + Decreased amortization costs+ Effects of cost reduction efforts+ 105 147 146 FY24Q3 YTD Total FY25Q3 YTD Total FY25Q3 Excluding FX Impact +39.8 % － One-time expenses related to the CGM business transfer Price increase / sales volume increase efforts in the U.S. +
Page 14
14 ©PHC Holdings Corporation 2026 +1.1% 64 54 54 379 392 392 499 507 507 FY24Q3 YTD Total FY25Q3 YTD Total FY25Q3 Excluding FX Impact 942 952 952 [Healthcare Solutions Segment] Revenue and Operating Profit Revenue increased YoY, driven by higher sales from genetic testing in LSI Medience and EMR/medical-receipt systems in Healthcare IT Solutions, which offset declines in e-prescription product sales and CRO business revenue. However, despite revenue growth and cost reduction efforts, operating profit decreased due to decreased e-prescription sales, rising procurement costs, higher amortization expenses, and reduced CRO revenue. Growth in EMR/medical-receipt system sales + Decline in demand for e-prescription products － Increased sales of genetic testing+ Healthcare IT Solutions LSIM CRO Decreased orders in clinical trials－ FY24Q3 YTD Total FY25Q3 YTD Total FY25Q3 Excluding FX Impact 134 129 129 ［Reference］Adjusted EBITDA • Margin: 5.2% *Please refer to page 25 for details. Operating ProfitRevenue Decreased large-scale testing－ Impact of increased revenue+ － Declined high-margin e-prescription product sales Increased procurement costs－ Decreased revenue in CRO business － Increased amortization costs due to new product launches － JPY 60M impact from corporate function transfer* － Effect of cost reductions+ (JPY in 100 millions) (JPY in 100 millions) 60 49 49 FY24Q3 YTD Total FY25Q3 YTD Total FY25Q3 Excluding FX Impact -17.3%
Page 15
15 ©PHC Holdings Corporation 2026 147 132 132 382 366 366 432 426 426 FY24Q3 YTD Total FY25Q3 YTD Total FY25Q3 Excluding FX Impact 961 924 924 -3.8% [Diagnostics & Life Sciences Segment] Revenue and Operating Profit Despite increased revenue in Europe due to solid performance in the Pathology business and favorable FX, overall revenue declined due to slow equipment demand in the U.S., lower revenue in IVD, and the absence of one- time income recorded in FY24. Operating profit significantly decreased YoY, despite cost reductions achieved through price revisions and supply chain optimization, largely due to lower revenue and tariff impacts. Biomedical lVD Pathology (JPY in 100 millions) (JPY in 100 millions) FY24Q3 YTD Total FY25Q3 YTD Total FY25Q3 Excluding FX Impact 147 106 106 ［Reference］Adjusted EBITDA *Please refer to page 25 for details. Operating ProfitRevenue • Margin: 2.5% Strong performance in Europe/Asia+ Recovery in Europe/Japan+ Stagnated equipment demand in the U.S. － Decreased sales in digital injectors－ Demand slowdown due to U.S. policy changes － Decline in reagent revenue－ Effect of pricing revision+ One-time income recorded in FY24－ Tariff impact of approx. JPY 1.5B－ － One-time income recorded in FY24 JPY 630M + Effect of pricing revision JPY 820M impact from corporate function transfer* － + Cost reduction initiatives (e.g., supply chain optimization) Impact of decreased revenue － 67 23 23 FY24Q3 YTD Total FY25Q3 YTD Total FY25Q3 Excluding FX Impact -65.2% Mid-sized volume demand for U.S. companies + + Other income from re-classification of affiliate of approx. JPY 500M
Page 16
16 ©PHC Holdings Corporation 2026 Revenue by Region In Japan, despite growth in Healthcare IT Solutions and LSIM, revenue remained flat YoY due to declines in CRO and IVD. In Europe, revenue increased due to solid performance in BGM and Pathology, as well as favorable FX. In North America, despite growth in Diabetes Management, revenue declined due to D&LS and FX. In Others, revenue increased as growth in other sales offset declines in BGM and IVD. Revenue CompositionFY24Q3 YTD Results FY25Q3 YTD Results Variance Variance (%) Japan 1,132 1,133 +1 +0.1% Europe 633 676 +44 +6.9% North America 595 565 -30 -5.0% Others 309 318 +8 +2.6% Total 2,669 2,693 +23 +0.9% (JPY in 100 millions) (JPY in 100 millions) Japan 42% Europe 25% North America 21% Others 12% Revenue 2,693
Page 17
17 ©PHC Holdings Corporation 2026 FY24Q3 YTD Results FY25Q3 YTD Results DM HS D&LS HQ & Others Consolidated DM HS D&LS HQ & Others Consolidated Operating Profit* 10,544 5,959 6,722 -6,197 17,028 14,737 4,929 2,337 -4,895 17,108 + Depreciation 4,951 7,445 8,458 484 21,338 3,524 7,802 8,506 447 20,280 + Impairment loss (excluding marketable securities) -80 - - -36 -117 - - 1 - 1 EBITDA 15,415 13,404 15,180 -5,749 38,250 18,261 12,731 10,845 -4,448 37,390 + Transformational M&A pre-acquisition and integration costs - 26 - 0 27 - 119 - - 119 + Restructuring 373 - 134 157 666 640 - 2 262 905 + Disposal / sale of asset - - - - - - - - - - + Special compensation to employees - - - - - - - - - - + Other one-time income / expense -8 - -631 4 -636 - - -278 - -278 Adjusted EBITDA 15,780 13,431 14,683 -5,587 38,307 18,901 12,851 10,569 -4,185 38,136 (JPY in millions) Reconciliation for Adjusted EBITDA *Corporate functions have been reviewed. Please refer to page 25 for details.
Page 18
18 ©PHC Holdings Corporation 2026 Key Consolidated Balance Sheet Information Goodwill increased by JPY 13.8 billion due to FX impact. Despite a net repayment of JPY 16.8 billion, the debt balance decreased by JPY 8.8 billion due to FX effects. Borrowings maturing in June 2026 were booked as current liabilities. FY24 End of March FY25 End of December Variance Cash and cash equivalents 396 449 +53 Total current assets 1,728 1,892 +164 Property, plant and equipment 484 438 -45 Goodwill 2,065 2,203 +138 Intangible assets 806 764 -43 Total noncurrent assets 3,597 3,634 +37 Total Assets 5,325 5,527 +202 Borrowings (current portion) 343 2,434 +2,091 Total current liabilities 1,406 3,612 +2,206 Borrowings (noncurrent portion) 2,210 31 -2,179 Total noncurrent liabilities 2,508 329 -2,179 Total liabilities 3,913 3,941 +27 Equity attributable to owners of parent 1,416 1,593 +176 Non-controlling interests -5 -7 -2 Total Liabilities and Net Assets 5,325 5,527 +202 Gross debt 2,553 2,465 -88 Gross Debt / Adjusted EBITDA*1 5.1x 4.9x - Net debt*2 2,157 2,016 -141 Net Debt / Adjusted EBITDA*1 4.3x 4.0x - ROE on Profit Attributable to Owners of Parent*1,3 7.5% 2.3% - (JPY in 100 millions) *1 Adjusted EBITDA and ROE are on last 12 months basis. *2 Calculated as: current and non-current borrowings - cash and cash equivalents. *3 Calculated as: profit attributable to owners of parent divided by average equity attributable to owners of parent during the period. These are not measures in accordance with IFRS Accounting Standards.
Page 19
19 ©PHC Holdings Corporation 2026 396 +25 +203 +42 +77 -39 -63 -62 +4 -168 -44 -51 +38 +64 449 FY25Q3 YTD Consolidated Cash Flow Operating CF totaled JPY +27.2 billion due to improved working capital, among other factors. Financing CF was JPY -22.6 billion, primarily due to JPY 16.8 billion in debt repayments and JPY 5.1 billion in dividend payments. Total CF amounted to JPY -1.1 billion, but the balance of cash and cash equivalents increased by JPY 5.3 billion due to favorable FX effects. FY24-end cash and cash equivalents FY25Q3-end cash and cash equivalents Profit before tax Depreciation and amortization CAPEX Others Repayment of debt Others FX Impact Investing CF -58 Financing CF -226 Dividend Repayment of lease liabilities Operating CF +272 OthersInterest expenses Interest paid Income taxes paid +28 Working capital (JPY in 100 millions)
Page 20
FY25 Full Year Forecasts 03
Page 21
21 ©PHC Holdings Corporation 2026 FY25 Full Year Consolidated Forecasts FY24 Results FY25 Forecast (As of Nov) FY25 Forecast (As of Feb) YoY Variance Change from Previous Forecast Comments Revenue 3,616 3,631 3,631 +15 - Operating Profit 226 200 200 -26 - Profit Before Tax 188 80 44 -144 -36 Profit Attributable to Owners of Parent 105 44 20 -85 -24 Basic Earnings Per Share (JPY) 83 35 16 -67 -19 EBITDA 504 461 461 -43 - Adjusted EBITDA 501 478 478 -23 - EUR/USD Against JPY 164 / 152 171 / 146 171 / 146 +7 / -6 - Annual Dividend (JPY) 42 42 42 - - (JPY in 100 millions)
Page 22
22 ©PHC Holdings Corporation 2026 FY24 Results FY25 Forecast YoY Variance* YoY Variance* (%) Revenue Diabetes Management 987 990 +3 +0.3% Healthcare Solutions 1,283 1,313 +30 +2.3% Diagnostics & Life Sciences 1,309 1,281 -28 -2.2% HQ & Others 37 48 +11 +30.8% Consolidated 3,616 3,631 +15 +0.4% Operating Profit* Diabetes Management 139 182 +43 +31.0% Healthcare Solutions 93 81 -12 -12.6% Diagnostics & Life Sciences 72 30 -42 -58.6% HQ & Others -78 -93 -15 - Consolidated 226 200 -26 -11.4% Adjusted EBITDA* Diabetes Management 204 234 +30 +14.5% Healthcare Solutions 193 188 -5 -2.3% Diagnostics & Life Sciences 181 137 -44 -24.3% HQ & Others -77 -81 -4 - Consolidated 501 478 -23 -4.6% FY25 Full Year Segment Forecasts (no change from previous forecast) (JPY in 100 millions) *Starting in FY25, corporate functions have been reviewed, and the impact amounts are included. Please refer to page 25 for details.
Page 23
23 ©PHC Holdings Corporation 2026 Updates on Impacts of U.S. Tariff Actions As for the potential risk after mitigation, the estimated annual impact is JPY 1.0-1.5 billion Mitigation Efforts • Optimization of the supply chain • Price increase • Cost reduction Current StatusAssumptions as of May Q1 Results • P&L impact is approx. JPY 200 million • Optimization of supply chain is progressing as planned. • Steel and aluminum tariffs have been in place since June 23. Q2 Results • From July 1, additional price increases have been applied to several products. • Starting August 7, new tax rates and additional tariffs on steel and aluminum products have been enforced. • P&L impact YTD: approx. JPY 800 million. Q3 Results • Positive effects of supply chain optimization and price increases initiated in Q1/Q2 continue to unfold. • P&L impact YTD: approx. JPY 1.5 billion. In Q4, the price increases are expected to offset the additional costs from tariffs. The forecast for the full-year impact remains at roughly JPY 1.5 billion, the previously stated upper end.
Page 24
Appendix 04
Page 25
25 ©PHC Holdings Corporation 2026 Impact of Corporate Function Review Starting in FY25, following the review of our corporate functions and the transfer of some headquarters roles to each business, the year-on-year variances include the impact of this change. The impact amounts for each segment are as follows. FY24 Results FY25 Forecast YoY Variance Impact of this change FY25Q3 YTD Impact Operating Profit Diabetes Management 139 182 +43 -4 -2 Healthcare Solutions 93 81 -12 -1 -1 Diagnostics & Life Sciences 72 30 -42 -16 -8 HQ & Others -78 -93 -15 +20 +11 Consolidated 226 200 -26 - - Adjusted EBITDA Diabetes Management 204 234 +30 -3 -2 Healthcare Solutions 193 188 -5 -1 -1 Diagnostics & Life Sciences 181 137 -44 -15 -8 HQ & Others -77 -81 -4 +20 +11 Consolidated 501 478 -23 - - (JPY in 100 millions)
Page 26
26 ©PHC Holdings Corporation 2026 FX Gains and Losses Recognized in Financial Income and Expenses FX gains and losses resulting from the settlement and FX valuation of receivables and payables denominated in foreign currencies. • FX valuation losses included in financial expenses for FY25 Q3 YTD: JPY 10.5 billion (Q1: JPY 4.4 billion, Q2: JPY 2.4 billion, Q3: JPY 3.6 billion) Due to the weaker JPY against the EUR at FY25Q3-end compared to FY24Q4-end, FX valuation losses were primarily incurred on the Company’s EUR-denominated borrowings from a subsidiary outside Japan. FX valuation gains or losses on these borrowings fluctuate with changes in the FX rate and these are unrealized. Since these are internal transactions, no external cash outflow occurs at settlement (excluding related cost). The corresponding FX translation impact on the EUR loan receivable held by the subsidiary outside Japan is included in other comprehensive income (OCI) which is part of the Group’s equity.
Page 27
27 ©PHC Holdings Corporation 2026 FX Sensitivity (JPY in millions) Currencies Pair Revenue Operating Profit JPY/EUR +400 0 JPY/USD +550 +35 PHC Group is exposed to the following impacts on its full year results depending on the respective change in exchange rates (depreciation of JPY 1 throughout the year). The Group is primarily affected by EUR and USD, besides JPY. The three currencies account for approx. 85% of revenue and nearly 100% of operating profit. The above figures are calculated based on the assumptions used in the original forecast and are not based on actual results.
Page 28
28 ©PHC Holdings Corporation 2026 Glossary *These are not measures in accordance with IFRS Accounting Standards. EBITDA EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities) Adjusted EBITDA Adjusted EBITDA = EBITDA + one-time income and expense Excluding FX Impact Excluding FX Impact is calculated as follows; - Revenue : IFRS Revenue – FX impact on Revenue - Operating Profit : IFRS Operating Profit – FX impact on Operating Profit - Adjusted EBITDA: Adjusted EBITDA – FX impact on Adjusted EBITDA DM Diabetes Management HS Healthcare Solutions D&LS Diagnostics & Life Sciences BGM Blood Glucose Monitoring CGM Continuous Glucose Monitoring IVD In Vitro Diagnostics Business Finance*
Page 29
29 ©PHC Holdings Corporation 2026 Historical Financial Data The following data are available on our website. Consolidated Balance Sheet Profit & Loss including adjustment items Cash Flow Statement Segment Revenue, Operating Profit, Adjusted EBITDA including adjustment items Revenues in each of the Business Units and Revenue Matrix of Segments and Regions Quarterly Data From FY23 to FY25Q3 Include: https:// www.phchd.com /global/ ir/historical